Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033150319> ?p ?o ?g. }
- W3033150319 abstract "Multiple myeloma is the second most common hematologic malignancy in the USA, with over 32,000 new cases and nearly 13,000 deaths expected in 2019. The past few decades in myeloma research have yielded significant advances, leading to the expansion of novel anti-myeloma agents. This review describes the incidence and mechanisms of cardiotoxicity for the FDA-approved proteasome inhibitors in myeloma and proposes strategies to assess and manage resultant cardiovascular adverse events. Proteasome inhibition precipitates protein aggregation and alters transcriptional activation of NF-κB targets which contributes to a pro-apoptotic signaling cascade in myeloma cells. Similar effects in cardiomyocytes and vascular smooth muscle endothelium, along with off-target downregulation of autophagy and signaling alterations of nitric oxide homeostasis, may be linked to observed cardiotoxic effects. There is preliminary evidence for cardioprotective potential for rutin, dexrazoxane, and apremilast that could have clinical applicability in the future. Of the proteasome inhibitors used in clinical practice, carfilzomib is the most strongly associated with cardiotoxicity. Patients with anticipated carfilzomib treatment should undergo assessment and optimization of baseline cardiovascular risk, with close monitoring during treatment. Previous clinical trials were not specifically designed to assess proteasome inhibitor-related cardiotoxicity, creating a need for future studies to identify and risk stratify vulnerable individuals and to develop potential cardioprotective strategies in attenuating cardiac injury." @default.
- W3033150319 created "2020-06-12" @default.
- W3033150319 creator A5002248011 @default.
- W3033150319 creator A5024821985 @default.
- W3033150319 creator A5067542535 @default.
- W3033150319 creator A5075120074 @default.
- W3033150319 date "2020-06-08" @default.
- W3033150319 modified "2023-10-10" @default.
- W3033150319 title "Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management" @default.
- W3033150319 cites W1497973518 @default.
- W3033150319 cites W1537635966 @default.
- W3033150319 cites W1968769311 @default.
- W3033150319 cites W1972774655 @default.
- W3033150319 cites W1985864219 @default.
- W3033150319 cites W1986036865 @default.
- W3033150319 cites W1994036267 @default.
- W3033150319 cites W2001786657 @default.
- W3033150319 cites W2001972347 @default.
- W3033150319 cites W2003504771 @default.
- W3033150319 cites W2007737411 @default.
- W3033150319 cites W2010163650 @default.
- W3033150319 cites W2016742872 @default.
- W3033150319 cites W2026642838 @default.
- W3033150319 cites W2027152656 @default.
- W3033150319 cites W2028945760 @default.
- W3033150319 cites W2037017311 @default.
- W3033150319 cites W2038675473 @default.
- W3033150319 cites W2039180923 @default.
- W3033150319 cites W2041460501 @default.
- W3033150319 cites W2050744280 @default.
- W3033150319 cites W2054898931 @default.
- W3033150319 cites W2056804811 @default.
- W3033150319 cites W2062629975 @default.
- W3033150319 cites W2069866232 @default.
- W3033150319 cites W2070367241 @default.
- W3033150319 cites W2070790769 @default.
- W3033150319 cites W2072651194 @default.
- W3033150319 cites W2084843323 @default.
- W3033150319 cites W2085449719 @default.
- W3033150319 cites W2089311432 @default.
- W3033150319 cites W2090416672 @default.
- W3033150319 cites W2091378741 @default.
- W3033150319 cites W2091548211 @default.
- W3033150319 cites W2094580473 @default.
- W3033150319 cites W2096207943 @default.
- W3033150319 cites W2100940126 @default.
- W3033150319 cites W2102088366 @default.
- W3033150319 cites W2104507960 @default.
- W3033150319 cites W2106692847 @default.
- W3033150319 cites W2107089546 @default.
- W3033150319 cites W2109371953 @default.
- W3033150319 cites W2111650326 @default.
- W3033150319 cites W2112238086 @default.
- W3033150319 cites W2120780398 @default.
- W3033150319 cites W2121420099 @default.
- W3033150319 cites W2126267349 @default.
- W3033150319 cites W2128863027 @default.
- W3033150319 cites W2131259241 @default.
- W3033150319 cites W2131394075 @default.
- W3033150319 cites W2132145608 @default.
- W3033150319 cites W2134902298 @default.
- W3033150319 cites W2144728882 @default.
- W3033150319 cites W2149030597 @default.
- W3033150319 cites W2154343997 @default.
- W3033150319 cites W2156098757 @default.
- W3033150319 cites W2156210785 @default.
- W3033150319 cites W2156302614 @default.
- W3033150319 cites W2160088903 @default.
- W3033150319 cites W2161111822 @default.
- W3033150319 cites W2166661413 @default.
- W3033150319 cites W2166747788 @default.
- W3033150319 cites W2169182236 @default.
- W3033150319 cites W2169183166 @default.
- W3033150319 cites W2186114039 @default.
- W3033150319 cites W2193716145 @default.
- W3033150319 cites W2234403337 @default.
- W3033150319 cites W2257690238 @default.
- W3033150319 cites W2273608446 @default.
- W3033150319 cites W2275275737 @default.
- W3033150319 cites W2278903892 @default.
- W3033150319 cites W2291965619 @default.
- W3033150319 cites W2343386476 @default.
- W3033150319 cites W2344865582 @default.
- W3033150319 cites W2346132062 @default.
- W3033150319 cites W2415425894 @default.
- W3033150319 cites W2416137380 @default.
- W3033150319 cites W2467918428 @default.
- W3033150319 cites W2533322662 @default.
- W3033150319 cites W2543255080 @default.
- W3033150319 cites W2547035585 @default.
- W3033150319 cites W2565335096 @default.
- W3033150319 cites W2573422825 @default.
- W3033150319 cites W2573690866 @default.
- W3033150319 cites W2589820061 @default.
- W3033150319 cites W2593723184 @default.
- W3033150319 cites W2602163408 @default.
- W3033150319 cites W2617671079 @default.
- W3033150319 cites W2618223593 @default.
- W3033150319 cites W2749746182 @default.
- W3033150319 cites W2766826981 @default.